The precipitous decline marks a reversal for the company, which had previously painted a bullish picture of its market access. During a March 2025 earnings call, CEO Richard Lowenthal projected that the company would achieve over 80% prior authorization coverage by the summer, bolstered by inclusion in the Caremark formulary. Chief Commercial Officer Eric Karas added to these expectations, targeting 60% commercial coverage by the end of the first quarter. Neither objective was met in the subsequent July 2026 payer cycle.

Legal representatives at Levi & Korsinsky are now examining whether these executive statements, combined with an April 29, 2026, proxy filing claiming 90% overall commercial coverage, misled shareholders. The filing made no mention of the potential for a stagnant July review cycle, leaving investors unprepared for the disclosure that resulted in the double-digit drop in share value. The investigation focuses on the discrepancy between the company’s public assurances of broad, unrestricted access and the reality of the zero-growth formulary outcome.